news
-
6 October 2005Kuros Biosurgery raises CHF 5.6 million (€ 3.6 million) in additional funding
Kuros Biosurgery AG is pleased to announce that the Company has raised CHF 5.6m in additional venture capital funding, fully subscribed by the Company’s existing investors (Venture Incubator, NeoMed Management, CDC Entreprises, Genevest Consulting Group, Vinci Capital and DEFI Gestion) and some of the Company’s employees.
Including this round and corporate collaborations, Kuros has now secured a total of CHF 47m (€ 30.4m) in external financing to advance its technology and product development activities.
Kuros is a private company based in Zurich, Switzerland, developing novel therapies for biosurgery, tissue repair and regeneration. The company is a spin-off from the Swiss Federal Institute, ETHZ and University of Zurich. For more information, please visit www.kuros.ch.
Related
Kuros announces results of one-month follow-up of Phase IIa trial of KUR-212 in patients with burns requiring mesh grafting
Baxter and Kuros announce product license and collaboration agreement
Kuros Biosurgery secures option for CHF 6.1 million (€ 4 million) for a second financing round
Kuros Biosurgery closes CHF 10.2 million (€ 7 million) first financing round